Barclays’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$316K Sell
89,970
-302,934
-77% -$1.24M ﹤0.01% 3450
2025
Q4
$1.32M Buy
392,904
+95,586
+32% +$248K ﹤0.01% 3241
2025
Q3
$389K Sell
297,318
-68,132
-19% -$70.5K ﹤0.01% 3957
2025
Q2
$262K Buy
365,450
+36,061
+11% +$28.3K ﹤0.01% 4115
2025
Q1
$484K Sell
329,389
-39,887
-11% -$95K ﹤0.01% 3553
2024
Q4
$1.64M Sell
369,276
-47,044
-11% -$191K ﹤0.01% 3051
2024
Q3
$1.72M Buy
416,320
+219,304
+111% +$1.18M ﹤0.01% 2978
2024
Q2
$1.28M Sell
197,016
-93,229
-32% -$659K ﹤0.01% 2447
2024
Q1
$2.53M Sell
290,245
-262,323
-47% -$3.18M ﹤0.01% 2381
2023
Q4
$6.32M Sell
552,568
-26,104
-5% -$258K ﹤0.01% 1897
2023
Q3
$5.57M Buy
578,672
+123,874
+27% +$1.21M ﹤0.01% 1263
2023
Q2
$4.84M Buy
454,798
+121,785
+37% +$1.31M ﹤0.01% 1367
2023
Q1
$3.5M Sell
333,013
-143,186
-30% -$1.6M ﹤0.01% 1785
2022
Q4
$5.9M Sell
476,199
-98,296
-17% -$1.12M ﹤0.01% 1506
2022
Q3
$5.95M Buy
574,495
+453,988
+377% +$5.15M 0.01% 1064
2022
Q2
$1.39M Sell
120,507
-335,591
-74% -$3.95M ﹤0.01% 2108
2022
Q1
$5.74M Buy
456,098
+233,894
+105% +$2.68M ﹤0.01% 1173
2021
Q4
$2.59M Buy
222,204
+6,488
+3% +$79.6K ﹤0.01% 2210
2021
Q3
$2.82M Sell
215,716
-9,639
-4% -$125K ﹤0.01% 2067
2021
Q2
$2.9M Sell
225,355
-217,046
-49% -$2.48M ﹤0.01% 1936
2021
Q1
$4.95M Buy
442,401
+65,173
+17% +$688K ﹤0.01% 1525
2020
Q4
$4.3M Sell
377,228
-114,182
-23% -$1.25M ﹤0.01% 1616
2020
Q3
$4.42M Buy
491,410
+214,377
+77% +$2.13M ﹤0.01% 1476
2020
Q2
$2.86M Buy
277,033
+46,565
+20% +$477K ﹤0.01% 1798
2020
Q1
$2.33M Buy
230,468
+62,652
+37% +$736K ﹤0.01% 2157
2019
Q4
$2.23M Buy
167,816
+70,667
+73% +$779K ﹤0.01% 2885
2019
Q3
$833K Sell
97,149
-51,879
-35% -$504K ﹤0.01% 3827
2019
Q2
$1.63M Sell
149,028
-140,875
-49% -$1.58M ﹤0.01% 3157
2019
Q1
$3.29M Buy
289,903
+72,883
+34% +$814K ﹤0.01% 2047
2018
Q4
$1.88M Buy
217,020
+137,096
+172% +$1.57M ﹤0.01% 2469
2018
Q3
$1.24M Buy
79,924
+67,806
+560% +$1.07M ﹤0.01% 3429
2018
Q2
$194K Sell
12,118
-27,499
-69% -$407K ﹤0.01% 4748
2018
Q1
$511K Sell
39,617
-144,466
-78% -$1.8M ﹤0.01% 3953
2017
Q4
$2.31M Buy
184,083
+177,994
+2,923% +$2.32M ﹤0.01% 2298
2017
Q3
$80K Buy
6,089
+4,602
+309% +$63.3K ﹤0.01% 5080
2017
Q2
$24K Sell
1,487
-3,468
-70% -$50.4K ﹤0.01% 5704
2017
Q1
$71K Sell
4,955
-11,660
-70% -$159K ﹤0.01% 5125
2016
Q4
$213K Sell
16,615
-522
-3% -$6.59K ﹤0.01% 4171
2016
Q3
$227K Sell
17,137
-199,001
-92% -$2.33M ﹤0.01% 3865
2016
Q2
$2.37M Buy
216,138
+146,103
+209% +$1.43M ﹤0.01% 1875
2016
Q1
$587K Buy
70,035
+25,338
+57% +$209K ﹤0.01% 3016
2015
Q4
$412K Sell
44,697
-62,900
-58% -$608K ﹤0.01% 3355
2015
Q3
$902K Buy
107,597
+26,631
+33% +$248K ﹤0.01% 2825
2015
Q2
$813K Buy
80,966
+68,232
+536% +$793K ﹤0.01% 3071
2015
Q1
$171K Sell
12,734
-4,228
-25% -$55.5K ﹤0.01% 4462
2014
Q4
$214K Sell
16,962
-4,682
-22% -$53.6K ﹤0.01% 4577
2014
Q3
$217K Sell
21,644
-141,028
-87% -$1.61M ﹤0.01% 4686
2014
Q2
$2.04M Buy
162,672
+137,432
+545% +$1.49M ﹤0.01% 2572
2014
Q1
$253K Buy
25,240
+11,039
+78% +$124K ﹤0.01% 4574
2013
Q4
$132K Sell
14,201
-34,416
-71% -$309K ﹤0.01% 5399
2013
Q3
$447K Sell
48,617
-109,855
-69% -$1.08M ﹤0.01% 4239
2013
Q2
$1.32M Buy
+158,472
New +$1.92M ﹤0.01% 3029

Other funds holding IRWD

Barclays's IRWD Position: Q1 2026 in Review

Barclays reduced its Ironwood Pharmaceuticals (IRWD) stake by 77% in Q1 2026, selling an estimated $1.24M and leaving 89,970 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #3450.

Barclays first reported a position in IRWD in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.32M in Q4 2023. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Barclays held 89,970 shares of Ironwood Pharmaceuticals worth $316K as of Q1 2026.
  • Barclays sold 302,934 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $1.24M.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3450 holding.
  • Barclays first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Ironwood Pharmaceuticals position peaked at $6.32M in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.